VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection.
Located in Baltimore, Maryland, VerImmune is an Immuno-Oncology company developing a first-in-class cancer therapy known as Anti-tumor Immune Redirection. This strategy utilizes a proprietary tumor-specific, tumor type agnostic, virus-inspired platform termed Anti-tumor Immune Redirection Virus-inspired Particles (AIR-ViPs) that redirects pre-existing pathogenic or childhood vaccine immune memory towards tumors.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 27, 2022 | Seed | $2.50M | 7 | SeedFolio | — | Detail |
May 6, 2020 | Grant | $855.84K | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
SeedFolio | Yes | Seed |
National Science Foundation | Yes | Grant |
Gaingels | — | Seed |
Mana Ventures | — | Seed |
Prox Ventures | — | Seed |
Proxima Ventures Ltd | — | Seed |
Tech Coast Angels San Diego | — | Seed |
Ulu Ventures | — | Seed |